Market Closed -
Nasdaq
04:00:00 2024-05-13 pm EDT
5-day change
1st Jan Change
0.82
USD
+16.31%
+7.02%
+43.16%
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Vaxart Business ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 13
CI
Earnings Flash (VXRT) VAXART Reports Q1 Revenue $2.2M, vs. Street Est of $0.8M
May. 13
MT
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 14
CI
Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024
Mar. 14
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall
Mar. 06
MT
Vaxart, Inc. Announces Chief Executive Officer Changes
Mar. 06
CI
Vaxart, Inc. Announces Management Appointments
Mar. 06
CI
North American Morning Briefing : Stock Futures -2-
Feb. 01
DJ
B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50
Jan. 31
MT
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study
Jan. 19
MT
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise
Jan. 16
MT
Vaxart, Inc. Announces CEO Changes
Jan. 16
CI
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director
Jan. 16
CI
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Dec. 21
CI
Transcript : Vaxart, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Nov. 02
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 02
CI
Earnings Flash (VXRT) VAXART Posts Q3 Revenue $2.1M
Nov. 02
MT
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers
Nov. 02
CI
Vaxart Says Topline Data From Phase 2 Challenge Study of Monovalent Norovirus Vaccine Meets 5 of 6 Endpoints
23-09-06
MT
Transcript : Vaxart, Inc. - Special Call
23-09-06
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate
23-09-06
CI
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating
23-08-07
MT
Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-03
CI
Transcript : Vaxart, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
More about the company
Last Close Price
0.82
USD
Average target price
5
USD
Spread / Average Target
+509.76%
Consensus
1st Jan change
Capi.
+43.16% 145M +5.66% 111B +11.23% 105B -2.94% 21.93B -12.15% 22.34B -5.48% 18.59B -36.52% 18.12B -10.09% 16.96B +3.33% 13.7B +36.58% 12.45B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1